4
MARKET OVERVIEW
Maps the market evolution with focus on trend catalysts, risk factors, and growth opportunities across segments.
4.3
INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
4.4
STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5
INDUSTRY TRENDS
Captures industry movement, adoption patterns, and strategic signals across key end-use segments and regions.
5.1
PORTER'S FIVE FORCES ANALYSIS
5.2
MACROECONOMIC INDICATORS
5.2.2
GDP TRENDS & FORECAST
5.2.3
TRENDS IN US MOLECULAR DIAGNOSTICS INDUSTRY
5.5.1
AVERAGE SELLING PRICE TREND OF KEY PLAYERS (2024–2026)
5.5.2
AVERAGE SELLING PRICE TREND OF MOLECULAR DIAGNOSTIC INSTRUMENTS, BY TYPE (2024–2026)
5.7
KEY CONFERENCES & EVENTS, 2026–2027
5.8
TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
5.9
INVESTMENT & FUNDING SCENARIO
5.10
IMPACT OF 2025 US TARIFFS ON US MOLECULAR DIAGNOSTICS MARKET
5.10.3
PRICE IMPACT ANALYSIS
5.10.4
IMPACT ON END-USER INDUSTRIES
6
STRATEGIC DISRUPTIONS THROUGH TECHNOLOGY, PATENTS, AND DIGITAL & AI ADOPTION
6.1
KEY EMERGING TECHNOLOGIES
6.2
COMPLEMENTARY TECHNOLOGIES
6.3
TECHNOLOGY/PRODUCT ROADMAP
6.5
IMPACT OF AI/GEN AI ON US MOLECULAR DIAGNOSTICS MARKET
6.5.1
TOP USE CASES & MARKET POTENTIAL
6.5.2
CASE STUDIES OF AI IMPLEMENTATION IN US MOLECULAR DIAGNOSTICS MARKET
6.5.3
INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
6.5.4
CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN US MOLECULAR DIAGNOSTICS MARKET
7.1
REGIONAL REGULATIONS & COMPLIANCE
7.1.1
REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
8
CUSTOMER LANDSCAPE & BUYER BEHAVIOR
8.1
DECISION-MAKING PROCESS
8.2
BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
8.3
ADOPTION BARRIERS & INTERNAL CHALLENGES
8.4
UNMET NEEDS FROM VARIOUS END-USER INDUSTRIES
9
US MOLECULAR DIAGNOSTICS MARKET, BY PRODUCT & SERVICE (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
10
US MOLECULAR DIAGNOSTICS MARKET, BY TEST TYPE (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
11
US MOLECULAR DIAGNOSTICS MARKET, BY SAMPLE TYPE (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
11.2
BLOOD, SERUM, AND PLASMA
12
US MOLECULAR DIAGNOSTICS MARKET, BY TECHNOLOGY (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
12.2
POLYMERASE CHAIN REACTION
12.3
ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
12.4
DNA SEQUENCING & NEXT-GENERATION SEQUENCING
12.5
IN SITU HYBRIDIZATION
13
US MOLECULAR DIAGNOSTICS MARKET, BY APPLICATION (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
13.2
INFECTIOUS DISEASE DIAGNOSTICS
13.2.1
SEXUALLY TRANSMITTED DISEASES
13.2.1.5
OTHER SEXUALLY TRANSMITTED DISEASES
13.2.2.3
OTHER HEPATITIS DISEASES
13.2.3
RESPIRATORY INFECTIOUS DISEASES
13.2.3.4
OTHER RESPIRATORY INFECTIOUS DISEASES
13.2.4
HOSPITAL-ACQUIRED INFECTIONS
13.2.5
VECTOR-BORNE DISEASES
13.2.6
OTHER INFECTIOUS DISEASES
13.3.5
OTHER CANCER TYPES
14
US MOLECULAR DIAGNOSTICS MARKET, BY TECHNIQUE (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
15
US MOLECULAR DIAGNOSTICS MARKET, BY CLINICAL APPLICATION (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
16
US MOLECULAR DIAGNOSTICS MARKET, BY END USER (MARKET SIZE & FORECAST TO 2031 – USD MILLION)
16.3
DIAGNOSTIC LABORATORIES
17.2
KEY PLAYER STRATEGIES/RIGHT TO WIN
17.3
REVENUE ANALYSIS, 2021–2025
17.4
MARKET SHARE ANALYSIS,
17.5
COMPANY VALUATION & FINANCIAL METRICS
17.7
COMPANY EVALUATION MATRIX: KEY PLAYERS,
17.7.5
COMPANY FOOTPRINT: KEY PLAYERS,
17.7.5.1
COMPANY FOOTPRINT
17.7.5.2
PRODUCT & SERVICE
17.7.5.3
TEST TYPE FOOTPRINT
17.7.5.4
SAMPLE TYPE FOOTPRINT
17.7.5.5
APPLICATION FOOTPRINT
17.8
COMPANY EVALUATION MATRIX: STARTUPS/SMES,
17.8.1
PROGRESSIVE COMPANIES
17.8.2
RESPONSIVE COMPANIES
17.8.5
COMPETITIVE BENCHMARKING: STARTUPS/SMES,
17.8.5.1
DETAILED LIST OF KEY STARTUPS/SMES
17.8.5.2
COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
17.9
COMPETITIVE SITUATION
18.1.1
DANAHER CORPORATION
18.1.2
F. HOFFMANN-LA ROCHE LTD.
18.1.4
SIEMENS HEALTHINEERS AG
18.1.5
THERMO FISHER SCIENTIFIC INC.
18.1.12
BECTON, DICKINSON AND COMPANY
18.1.13
MYRIAD GENETICS, INC.
18.1.14
QUIDELORTHO CORPORATION
18.1.17
EXACT SCIENCES CORPORATION
18.1.18
GENETIC SIGNATURES
18.2.1
AGILENT TECHNOLOGIES, INC.
18.2.4
BRUKER CORPORATION
18.2.6
AMOY DIAGNOSTICS CO., LTD.
19.1.1.1
KEY DATA FROM SECONDARY SOURCES
19.1.3
MARKET SIZE ESTIMATION
19.1.3.1
BOTTOM-UP APPROACH
19.1.3.2
TOP-DOWN APPROACH
19.1.3.3
BASE NUMBER CALCULATION
19.1.4
MARKET FORECAST APPROACH
19.1.5
DATA TRIANGULATION
19.1.7
RESEARCH ASSUMPTIONS
19.1.8
RESEARCH LIMITATIONS & RISK ASSESSMENT
20.2
KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
20.3
CUSTOMIZATION OPTIONS
Growth opportunities and latent adjacency in US Molecular Diagnostics Market